Unibest

Pharmaceutical intermediates

Semaglutide Intermediates

3 pharmaceutical intermediates for Semaglutide. Indication: Diabetes Mellitus, Type 2; Overweight.

提交项目All intermediates

About Semaglutide

Originator
Novo Nordisk Inc
Indication
Diabetes Mellitus, Type 2; Overweight
Approved Date
09/20/2019
DS/DP
03/20/2026

Available intermediates

3 intermediates currently listed for Semaglutide. Request specifications, documentation or a quotation for any item below.

Semaglutide intermediates
Product NameCAS No.Molecular FormulaPhysical Properties
AEEA-HCl134979-01-4//
AEEA-AEEA1143516-05-5//
Boc-AEEA-AEEA1069067-08-8//

Other programs under S

SaracatinibSarecycline HydrochlorideSarolanerSaxagliptinSeladelparSeltorexantSitafloxacin hydrate Sofosbuvir

Building toward Semaglutide?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

提交项目 联系团队

我们能如何帮助您？

获取最新活动与法规动态洞察

直接发送到您的邮箱

在此获取行业洞察与 Unibest 动态

联系我们 →